Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
netFormulary
Home
Treatment Use
Class
Chapters
News
Reports
Contact
SEARCH
Searching for :
Upadacitinib
Open monograph to display formulary status.
Formulary items found
Status
Description
Section
RED
Upadacitinib Rinvoq
®
(15mg, 30mg and 45mg p/r tablets)
Skin, Drugs affecting the immune response, 13.05.03
RED
Upadacitinib Rinvoq
®
(15mg, 30mg and 45mg p/r tablets)
Gastro-intestinal system, Cytokine inhibitors, 01.05.03
RED
Upadacitinib RINVOQ
®
(15 mg Polonged-release tablets)
Musculoskeletal and joint diseases, Drugs which suppress the rheumatic disease process, 10.01.03
Links found
NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis
NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
NICE TA829: Upadacitinib for treating active ankylosing spondylitis
NICE TA856: Upadacitinib for treating moderately to severely active ulcerative colitis
NICE TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis
NICE TA905: Upadacitinib for previously treated moderately to severely active Crohn’s disease